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Key Points
• DPPIV (CD26) is a new
specific marker of CML LSC
that aids CML diagnostics
and the measurement,
characterization, and
purification of LSC.
• DPPIV on CML LSC degrades
SDF-1 and thereby promotes
the niche-escape of LSC,
which may contribute
to extramedullary
myeloproliferation in CML.
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the
BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are
well-defined, little is known about effector-molecules contributing to malignant expansion
and theextramedullaryspreadof leukemicSC (LSC) inCML.Wehave identified thecytokine-
targeting surface enzyme dipeptidylpeptidase-IV (DPPIV/CD26) as a novel, specific and
pathogenetically relevant biomarker of CD341/CD38─ CML LSC. In functional assays, CD26
was identified as target enzyme disrupting the SDF-1-CXCR4-axis by cleaving SDF-1,
a chemotaxin recruiting CXCR41 SC. CD26 was not detected on normal SC or LSC in other
hematopoietic malignancies. Correspondingly, CD261 LSC decreased to low or undetect-
able levels during successful treatment with imatinib. CD261 CML LSC engrafted NOD-
SCID-IL-2Rg2/2 (NSG) mice with BCR/ABL11 cells, whereas CD26─ SC from the same
patients produced multilineage BCR/ABL1– engraftment. Finally, targeting of CD26 by
gliptins suppressed the expansion of BCR/ABL11 cells. Together, CD26 is a new biomarker
and target of CML LSC. CD26 expression may explain the abnormal extramedullary spread
of CML LSC, and inhibition of CD26 may revert abnormal LSC function and support
curative treatment approaches in this malignancy. (Blood. 2014;123(25):3951-3962)
Introduction
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm
characterized by the reciprocal translocation t(9;22).1-3 The resulting
oncoprotein, BCR/ABL1, is considered essential for the initiation
and manifestation of the disease.2,3 In line with this assumption, the
BCR/ABL1 kinase inhibitor imatinib produces major and stable
cytogenetic responses in a majority of patients with chronic phase
(CP) CML.4,5 Nevertheless, in most patients, imatinib is unable to
eradicate the disease, a phenomenon that has been explained by in-
trinsic and acquired drug resistance in residual leukemic SC (LSC).6-11
Whereas intrinsic resistance is common to most or all LSC, acquired
resistance results from additional (subclone-speciﬁc) lesions, such as
BCR/ABL1 mutations.7-13
The concept of LSC is based on the assumption that only a subset
of leukemic cells display long-term self-renewal and thus leukemia-
propagating activity.12-16 This hypothesis has major implications for
the development of new curative treatment concepts.16-21 In fact,
current research focuses on LSC-speciﬁc drug targets and novel
drugs that can attack and eliminate LSC.17-21 However, the issue
of targeting LSC is complex.21 One important aspect is that LSC
interact with the SC-related bone marrow (BM) microenvironment,
the so called “SC niche” and thereby may escape natural control
mechanisms or drug effects.21-24
In CML, LSC supposedly reside within the CD341/CD38─/Lin─
fraction of the leukemic clone.7-10,25-27 However, normal hemato-
poietic SC also exhibit this phenotype so that additional markers are
required to discriminate CML LSC from normal SC. Recent data
suggest that CML LSC aberrantly express IL-1RAP.28 Moreover, it
has been described that CML LSC express higher levels of CD33
and CD123 compared with normal SC.29,30 Other studies have shown
that LSC in CML express several surface antigens that are relevant
for SC-niche interactions, including CD44 and CXCR4.31,32 The
latter antigen is of considerable importance because SC are usually
attracted into the SC niche by the chemotactic effect of stroma-
derived factor-1 (SDF-1), a ligand of CXCR4. However, although
Submitted October 31, 2013; accepted April 16, 2014. Prepublished online as
Blood First Edition paper, April 28, 2014; DOI 10.1182/blood-2013-10-536078.
H.H. and I.S. contributed equally to this study.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2014 by The American Society of Hematology
BLOOD, 19 JUNE 2014 x VOLUME 123, NUMBER 25 3951
For personal use only.on August 12, 2015. by guest  www.bloodjournal.orgFrom 
Figure 1. LSCs in CML express CD26. (A) Heat map analysis of gene array data of RNA isolated from sorted CD341/CD38─ SCs (left) or CD341/CD381 progenitor cells
(right) obtained from patients with chronic phase (CP) CML (n 5 4) and cord blood (CB) SC. Gene array analyses were performed as described in the supplemental material
available on the BloodWeb site. Expression levels were normalized to CB control. Top-regulated genes of interest are shown. (B) Heat map analysis of pPCR data (upper panel).
mRNA analyses were performed on sorted CD341/CD38─ SC (upper left) and CD341/CD381 cells (upper right) obtained from 3 CB samples and 4 patients with CML. Top-
regulated genes of interest are shown. Lower panel: qPCR analysis of expression of CD26 mRNA in sorted CD341/CD38─ SC (lower left) and CD341/CD381 cells (lower
right) obtained from 7 patients with CML and 3 CB samples. CD26 mRNA levels are expressed as percent of ABL. Results represent the mean6 SD (CML, n5 7; CB, n5 3).
(C) Multicolor flow cytometry analysis of CD26 expression on CD341/CD38─ SC in patients with CML (CP, n 5 33; AP, n 5 3; BP, n 5 2), normal/reactive BM (n 5 33), and
BM of patients with idiopathic cytopenia of unknown significance (ICUS) (n5 15), AML (n5 39), myelodysplastic syndrome (MDS) (n5 12), JAK2 V617F1 myeloproliferative
neoplasms (MPN) (n 5 6), MDS/MPN overlap disorders (n 5 5), and indolent systemic mastocytosis (ISM) (n 5 7). The upper panel shows the percentage of CD261 SC.
Boxes represent the 25th to 75th percentile. The lower subpanel shows representative staining examples: red indicates a positive staining-reaction, blue indicates a negative
stain. The isotype-matched control antibody is also shown (black open histograms). (D) The upper panel shows a FISH analysis of purified CD341/CD382/CD261 CML LSC
(left) and CD341/CD382/CD262 SC (right) in one CML patient. FISH was performed on cytospin slides using a triple color–staining approach, with 1 probe specific for ABL1
(red) and 2 (green and blue) specific for BCR. Red-green and red-blue fusion-spots indicate BCR/ABL1. Quantitative FISH data are shown in supplemental Table 13. Lower
panel: Percentage of BCR/ABL11 cells by FISH (left panel) and percent BCR/ABL1 mRNA relative to ABL mRNA (right panel) in sorted CD341/CD382/CD261 LSC and
CD341/CD382/CD262 SC from the same patients. FISH data are expressed as mean 6 SD from 3 patients, and BCR/ABL1 mRNA levels from sorted cells as mean 6 SD
from 4 different CML patients.
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CML LSC express CXCR4, their migratory response to SDF-1 is
poor compared with normal SC.31-33
In the present article, we show that CD341/CD38─/Lin─ CML
LSC speciﬁcally co-express dipeptidylpeptidase IV (DPPIV5CD26)
and that this enzyme disrupts LSC-niche interactions by degrading
SDF-1. Moreover, our data show that CD26 is a robust biomarker for
the quantiﬁcation and isolation of CML LSC.
Materials and methods
Patients and cell sampling
Eighty-eight patientswith CML (36 females, 52males) were examined. The
median age was 56 years (range 18-86). The patients’ characteristics are
shown in supplemental Table 1. Peripheral blood (PB) and/or BMcells were
collected at diagnosis and in the follow-up. Control cohorts are shown in
supplemental Table 2 (normal BM), supplemental Table 3 (idiopathic
cytopenia), supplemental Table 4 (other hematologic disorders), and sup-
plemental Table 5 (CD261 AML cases). All donors gave written informed
consent. All studies, including the examination of LSC and their growth in a
xenotransplantation mouse model, were approved by the local ethics com-
mittee of the Medical University of Vienna. Studies were conducted in
accordance with the Declaration of Helsinki.
Isolation of cells, phenotyping, and purification of LSC
Phenotyping of CD341/CD38─/Lin─ SC and CD341/CD381 progenitor
cells was performed by multicolor ﬂow cytometry as described29,30 using
CML samples (n 5 132) or control samples and antibodies shown in
supplemental Table 6. The gating algorithm is shown in supplemental
Figure 1A. In follow-up examinations, the percentage of CD261 SC was
determined in patients treated with imatinib or nilotinib. In 9 CML patients,
CD341/CD38─ SC and CD341/CD381 progenitor cells were puriﬁed from
mononuclear cells (MNC) by cell sorting as described,30 and in 14 CML
patients, the CD261 LSC fraction and CD26─ SC fraction of CD341/Lin─
cells were puriﬁed by cell sorting. A detailed description is provided in the
supplemental material.
Xenotransplantation assay
In xenotransplantation experiments, various subfractions of CML leukocytes
were injected intravenously into irradiated nonobese diabetic SCID-IL-2Rg2/2
(NSG) mice. A detailed description of mouse experiments is provided in the
supplemental Appendix.
In vitro culture experiments and chemotaxis assay
CML MNC, SC subfractions (CD341/CD38─/CD261, CD341/CD38─/
CD26─), and CD341/CD381 progenitor cells were cultured in a long-term
culture-initiating cell (LTC-IC) assay as described.30 CML MNC were
cultured in the absence or presence of vildagliptin (0.1-10mM) or sitagliptin
Table 1. Expression of surface antigens on CD341/CD382 and CD341/CD381 cells in patients with CML and in normal/reactive BM
Expression on CP CML cells Expression on AP CML cells Expression on normal BM cells
CD Antigen CD341/CD382 CD341/CD381 CD341/CD382 CD341/CD381 CD341/CD382 CD341/CD381
CD9 Tetraspanin 29 1 1 n.t. n.t. 1/2 1/2
CD25 IL-2RA 11 1/– 11 1 2 1/2
CD26 DPPIV 11 1/2 11 1/2 2 2
CD33 Siglec-3 11 11 11 11 1 11
CD36 TSPR 1/2 1 n.t. n.t. 2 1/2
CD41 ITGA2B 1 1 1/2 1/2 1 1
CD42b GP1BA 2 2 2 2 2 2
CD44 Pgp1 11 11 11 11 11 11
CD46 MCP 11 11 11 11 11 11
CD49f ITGA6B 1 1 1 1/2 1 1
CD52 CAMPATH 1 1/2 n.t. n.t. 1 1
CD62 SELP 2 2 2 2 2 2
CD90 Thy-1 1 1/2 n.t. n.t. 1 1/2
CD96 Tactile 2 2 2 2 2 2
CD105 Endoglin 11 11 11 11 1 1
CD114 G-CSFR 1 1/2 1 1/2 1 1
CD117 SCFR/KIT 11 11 11 11 11 11
CD123 IL-3RA 1 1 1 1 1/2 1
CD130 IL6ST 2 2 2 2 1/2 1/2
CD133 Prominin 1 11 1/2 11 1/2 11 11
CD135 FLT3 1 1/2 1 1/2 1 1
CD151 RAPH 1 1 1 1 1 1
CD164 Sialomucin 1 1 1 1 11 11
CD184 CXCR4 1 1 1 1 1 1
CD200 OX2 11 1 1 1 11 11
CD203c ENPP3 2 2 2 2 2 2
CD243 MDR1 2 2 2 2 2 2
CD271 NGF-R 2 2 n.t. n.t. 2 2
n.c. CLL1 1/2 1/2 n.t. n.t. 2 1/2
n.c. IL-1RAP 1 1 n.t. n.t. 2 1/2
n.c. NPDC1 1 1 n.t. n.t. 1 1
n.c. ROBO4 1 1/2 n.t. n.t. 1 1/2
CP, chronic phase; AP, accelerated phase; CLL1, C type lectin-like molecule 1; CML, chronic myeloid leukemia; DPPIV, dipeptidylpeptidase IV; G-CSF, granulocyte
colony-stimulating factor; IL-2, interleukin-2; n.c., not yet clustered; NGF, nerve growth factor; n.t., not tested; SCF, SC factor; TSPR, thrombospondin receptor; 11, strongly
expressed in a majority of cases; 1, clear expression in majority of cases; 1/2, expression in minority of cases or weak expression in majority of cases; 2, no expression in
a vast majority of cases.
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Figure 2. Clonogenic growth and in vivo repopulation of CML SCs. (A) Left: Sorted (.98% pure) CD341/CD382/CD262 SC, CD341/CD382/CD261 SC, and CD341/
CD381 sorted progenitor cells (CP CML) were plated in methylcellulose and incubated at 37°C for 16 days. Then CFU-GM–derived colonies were counted under an inverted
microscope (black bars). Thereafter, colonies were picked and BCR/ABL1 mRNA expression was determined by qPCR (white bars). Results represent the mean 6 SD of
triplicates. Right: Purified CD341/CD382/CD262, CD341/CD382/CD261, and CD341/CD381 cells were incubated on irradiated M2-10B4 feeder cells for 3 weeks.
Then cells were harvested and cultured in a CFU-GM assay. CFU-GM colonies (black bars) were counted by microscopy and BCR/ABL1 mRNA levels were determined by
qPCR (white bars). (B) Experimental setup of xenograft experiments with purified CML cells. First, CML cells (CP) were depleted from lineage1 cells and separated into
CD261 cells and CD262 cells by cell sorting (purity .98%). The 2 fractions were separately injected intravenously into irradiated NSG mice (0.1-0.8 3 106 CD261 cells per
mouse and 0.5-1.5 3 106 CD262 cells per mouse). (C) After 16 weeks or 28 weeks, flushed BM cells of NSG mice injected with CD262 cells (blue symbols) or CD261 cells
(red symbols) were analyzed for the presence of CD331 myeloid cells (circles) and CD191 B cells (triangles) by flow cytometry. (D) Flow cytometry patterns of engrafted cells
in 2 representative mice, one injected with CD262 SC, where multilineage BCR/ABL1– engraftment was found (upper panel) and one with CD261 SC, where engraftment with
BCR/ABL11 myeloid cells was seen (lower subpanel). The table shows a summary of engraftment results with percentages of human CD451 cells, CD331 cells, and CD191
cells, and the detection of BCR/ABL1 by qPCR. n.d., not determined.
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(0.1-10 mM). CML MNC or puriﬁed LSC were also cultured in short-term
suspension culture or in short-term methylcellulose cultures in the absence
or presence of vildagliptin or sitagliptin (0.1-10 mM). Colonies were
counted under an inverted microscope and examined for BCR/ABL1
mRNA expression by quantitative polymerase chain reaction (qPCR).
Migration of CXCR41 U937 cells or primary (sorted) CD341 CML cells
against SDF-1 was determined in a double-chamber chemotaxis assay as
reported.31,32 A detailed description of bioassays used in this study is
provided in the supplemental Methods.
Immunohistochemistry experiments
Immunohistochemistry was performed on formalin-ﬁxed and parafﬁn-
embedded BM sections obtained from patients with newly diagnosed CML,
and BM sections obtained from NSGmice injected with CD261 CML LSC
and CD26─ SC obtained from (the same) CML patients. The antibodies
used and the staining protocols are provided in supplemental Table 7. The
distribution of CML (progenitor) cells was investigated by microscopy and
documented by photography.
Gene array analysis, qPCR, and cytogenetics
Highly puriﬁed (sorted) CD341/CD38─ and CD341/CD381 cells from
CML CP or cord blood (CB) samples were subjected to RNA isolation and
gene array analysis using Affymetrix technology. Technical details are
provided in the supplemental material. A complete set of mRNA data are
available at Gene Expression Omnibus (accession #GSE40721). mRNA
expression levels (selected genes) were conﬁrmed by qPCR using primers
shown in supplemental Table 8. BCR/ABL1 and CD26 mRNA levels were
quantiﬁed in sortedCMLLSC,LTC-IC-derived or short-termculture-derived
colonies, andNSGmouse-engrafting cells. RNA isolation andPCRassays are
described in the supplemental material. ABL served as a reference gene. In
clinical follow-up samples, BCR/ABL1 mRNA levels were adjusted ac-
cording to the international scale (IS).34 Conventional cytogenetics and
ﬂuorescence in situ hybridization (FISH) were performed according to
published protocols.35
Statistical analysis
Differences in marker expression or the percentage of LSC in various sample
series were determined by statistical tests described in the supplemental
material.
Results
CD341/CD38─/Lin─ CML LSC express a unique phenotype
To identify novel robust markers and targets of LSC, we performed
gene array studies (Figure 1A) and qPCR analyses (Figure 1B) on
highly puriﬁed (.98% pure) CD341/CD38─ SC derived from pa-
tients with CP CML. In addition, ﬂow cytometry was performed
(Figure 1C and Table 1). Antigens that were clearly detectable not
only by gene array and qPCR, but also on the surface of LSC, were
CD9, CD25, CD26, CD33, CD36, CD44, CD52, CD90, CD105,
CD114, CD117, CD123, CD164, CD184, IL-1RAP, ROBO4, and
NPDC1. Several of these antigens were found to be expressed at
higher levels on the surface of CML LSC compared with normal SC
(supplemental Table 9). Three of these molecules, CD25, CD26, and
IL-1RAP, were found to be rather speciﬁcally (aberrantly) expressed
on CMLLSC but were not or were only weakly expressed on normal
SC (supplemental Figure 2A and Table 1). The most speciﬁc marker
of CML LSC appeared to be CD26 (supplemental Figure 2A).
Overall, there was a good correlation between expression of CD26
and CD25 and a less signiﬁcant correlation between expression of
CD26 and IL-1RAP on CML LSC, which appeared to be caused by
the fact that in several patients, LSC did not express IL-1RAP.
Supplemental Figure 2B shows the reactivity of LSCwith 3 different
CD26 mAb, and supplemental Tables 9-11 show an overview of
upregulated genes in CML LSC.
Identification of DPPIV (CD26) as a specific biomarker of
CML LSC
In consecutive validation experiments, only CD26 was found to
meet all requirements for a speciﬁc marker of CML LSC. In fact,
whereas CD25 and IL-1RAP are expressed on different types of
cells in the CML clone, expression of CD26 was found to be
restricted essentially to LSC and is otherwise only expressed on
basophils and T cells (supplemental Table 12). Second, whereas
IL-1RAP and CD25 are frequently expressed on LSC in acute
myeloid leukemia (AML) and other types of leukemias, CD26 was
only detectable on LSC in CML but not on SC in other myeloid
neoplasms, with the exception of a very few patients with AML
(Figure 1C and supplemental Figure 2A). As was determined by
FISH, nearly 100% of the puriﬁed CD261 LSC expressed BCR/
ABL1, whereas the CD26─ SC from the same patients were all
BCR/ABL1– (Figure 1D and supplemental Table 13). Expression
of BCR/ABL1 in CD261 CML LSC was also conﬁrmed by qPCR
(Figure 1D).
CD261 LSC exhibit long-term proliferation- and NSG
repopulation activity
In short-term colony assays and in LTC-ICs, colony cells derived
from CD261 LSC (obtained from CP CML patients) contained
BCR/ABL1mRNA,whereas cells of colonies derived fromCD26─SC
(from the same patients) did not contain BCR/ABL1 (Figure 2A). In
NSGmice, CD261LSCobtained fromCPCMLpatients were found
to produce a myeloid (granulo-monocytic) BCR/ABL11 engraft-
ment after 16 and 28 weeks, whereas CD26─ SC isolated from the
same patients (CP CML) produced BCR/ABL1– multilineage
(myeloid and B lineage) engraftment (Figure 2B-D). As expected,
the more mature CD34─myeloid cells (CD141, CD151) in CP CML
patients did not engraft or survive in NSG mice after 32 weeks
(Figure 3).
LSC-derived DPPIV (CD26) cleaves SDF-1 and facilitates a
SC escape from the BM niche, resulting in niche-independent
spread of leukemic cells
Highly puriﬁedCD341/CD38─/CD261CMLLSCexhibitedDPPIV
(CD26) enzymatic activity, whereas CD341/CD38─/CD26─ SC
from the same patients did not express DPPIV activity (Figure 3A).
TheDPPIV-targeting drugs sitagliptin and vildagliptinwere found to
block the activity of recombinant DPPIV, DPPIV transfected into
CML cells (KU812), and DPPIV obtained from primary CML LSC
(Figure 3A). In addition, recombinant DPPIV blocked the SDF-
1–induced migration of CXCR41U937 cells, and this DPPIV effect
was reverted by sitagliptin and vildagliptin (Figure 3B). The same
result was obtainedwith primaryCMLLSC (supplemental Figure 3).
Furthermore, we found that although gliptins did not affect colony
formation per se, gliptin exposure of CML LSC is associated with
reduced numbers of BCR/ABL11 colony-forming unit–granulocyte
macrophage (CFU-GM) in LTC-IC (Figure 3C). In addition, when
plated on M2-10B4 cells, short-term exposure of CML cells to
vildagliptin resulted in CFU depletion, presumably through (better)
attachment of SC to the stroma cell layer, and imatinib augmented
this gliptin-effect (Figure 3D). These drug effects were not seen with
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normal BMSC (supplemental Figure 4A-B). Collectively, these data
suggest that CD261 CML LSC escape from niche cells because of
disrupted SDF-1-CXCR4 interactions. Correspondingly, relative to
normal SC, the numbers of circulating CD261 CML LSC in our
CML patients were higher than BM LSC numbers (Figure 3E). The
escape hypothesis was further supported by data obtained in NSG
mice. In fact, whereas normal CD26─ SC isolated from our CML
patients engrafted near or at the endosteal layer (SC niche) in NSG
Figure 3. CML SC express functional DPPIV activity. (A) DPPIV enzyme activity of recombinant human (rh) DPPIV/CD26 (upper panel) and cell-derived CD26 (lower
panel) measured as described in the supplemental material. Upper right: rhCD26 (200 ng/mL) was preincubated with various concentrations of sitagliptin or vildagliptin (as
indicated) at 37°C for 30 minutes. Lower left: DPPIV activity in lysates of CD26-transfected KU812 cells (red bars) and control-vector–transfected CD262 KU812 cells (blue
bars) (each 50 3 103). Before being analyzed, cells were incubated with various concentrations of sitagliptin or vildagliptin for 30 minutes. Lower right: Primary sorted CD261
SC (red bars) and CD262 SC (blue bars) (each 25 3 103 cells) from a patient with CP CML were incubated with or without vildagliptin at 37°C for 30 minutes. DPPIV enzyme
activity was expressed as relative luminescence units (RLU) per 503 103 cells. Results represent the mean6 SD of triplicates. (B) For chemotactic migration, CXCR41 U937
cells (1.5 3 105/well) were applied in a double-chamber chemotaxis assay. Cells were allowed to migrate through 5-mm filters against various concentrations of SDF-1 (upper
left) at 37°C for 4 hours. Transmigrated cells were counted by flow cytometry. In a next step, SDF-1 (25 ng/mL) was incubated with various concentrations of rhCD26 overnight
and then used to induce migration of U937 cells (upper right subpanel). Finally, 200 ng/mL of rhCD26 were preincubated with various concentrations of sitagliptin (lower left) or
vildagliptin (lower right) for 30 minutes, before SDF-1 (25 ng/mL) was added (overnight). Results represent the mean 6 SD from 4 experiments. *P , .05 compared with
untreated cells. (C) Left: CML MNC were plated in methylcellulose supplemented with cytokines in the absence (control) or presence of various concentrations of vildagliptin at
37°C for 16 days. Then CFU-GM colonies (black bars) were counted. Thereafter, colonies were picked and BCR/ABL1 mRNA expression was determined by qPCR (white
bars). Right: CML MNC were incubated on irradiated M2-10B4 feeder cells for 3 weeks in the absence (control) or presence of various concentrations of vildagliptin. Then cells
were harvested and plated in a CFU assay for 16 days. CFU-GM colonies (black bars) and BCR/ABL11 colonies (white bars) are shown. *P , .05 compared with untreated
cells. (D) CML MNC were plated on a feeder layer of irradiated M2-10B4 cells in various concentrations of imatinib (left panel) or imatinib in combination with 10 mM vildagliptin
(right panel) for 48 hours. Thereafter, nonadherent cells of each well were harvested and plated in a CFU assay. After 2 weeks, colonies were counted. (E) The percentage of
CD261 and CD262 SC in the BM (left bars) and PB (right bars) of patients with CML determined by flow cytometry. (F) NSG mouse BM sections stained with an antibody
against human CD45. NSG mice were injected with CD261 SC, CD262 SC, lineage-positive (Lin1; CD141, CD151 sorted) cells (negative control), or CD3–depleted MNC
(positive control) obtained from patients with CP CML. CD261 LSC produced diffuse engraftment in the NSG BM, whereas normal CD262 SC produced myeloid engraftment
at the endosteal surface. Original magnification340/0.85. (F) Lower right: Engraftment of CD261 CML LSC after preincubation with control medium (2) or vildagliptin, 10 mM
(1) at 37°C for 30 minutes. Engraftment in NSG mice (3 mice per group) was determined by measuring the percentage of CD451 cells in the BM (after 18 weeks) by flow
cytometry. Results represent the mean6 SD of 3 mice (each group). (G) BCR/ABL1 transcript levels, quantified by qPCR, in 2 patients with imatinib-resistant CML who received
nilotinib (left panel patient: 200 mg/day; right panel patient: 800 mg/day), and later, because of uncontrolled diabetes mellitus, saxagliptin, 5 mg daily per os (left panel) or sitagliptin,
50 mg daily per os (right panel). (H) BCR/ABL1 mRNA levels in 8 CML patients (4 with high BCR/ABL1 burden and 4 with low BCR/ABL1 burden) who lost MMR or CMR during
therapy with nilotinib and did not receive a gliptin. BCR/ABL1 transcript levels were quantified by qPCR according to the international scale.
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mice, CD261 LSC from the same patients showed a diffuse en-
graftment pattern (Figure 3F). Such diffuse pattern of inﬁltration of
CD341 cells and CD261 cells was also found in our CML patients
(supplemental Figure 5).
Targeting of CD26 with gliptins suppresses the leukemic
spread in CML
To test the hypothesis that gliptin exposure redistributes CML LSC
back into the SC niche to control their subsequent spread, we
incubated primary CP CML LSC with vildagliptin before injecting
these cells into NSG mice. As is shown in Figure 3F, preincubation
of CML cells with vildagliptin resulted in reduced engraftment of
leukemic cells. We also screened our CML cohort for patients who
were treated with nilotinib but remained BCR/ABL11 and had
received a gliptin because of uncontrolled diabetes mellitus. We
identiﬁed 2 such patients. In both of them, BCR/ABL1 transcript
levels decreased during treatment with saxagliptin or sitagliptin
(Figure 3G). In other CML patients who had lost or did not achieve
major molecular remission (MMR) during nilotinib and did not
receive a gliptin, BCR/ABL1 continued to increase or remained
stable, but did not decrease (Figure 3H).
Regulation of expression of CD25, CD26, and CXCR4 on LSC
in CML
Although CD26 is speciﬁcally expressed on BCR/ABL11 LSC,
BCR/ABL1 did not induce expression of CD26 in Mo7e cells
(supplemental Figure 6A) or Ba/F3 cells (not shown), and only a
marginal increase inCD25mRNAwas seen (supplemental Figure 6A).
Moreover, imatinib did not block expression of CD25 or CD26 in
CMLLSC(supplemental Figure 6B-C).Nilotinibwas found toslightly
downregulate expression of CD25 and CD26 on CML LSC (sup-
plemental Figure 6B). We also found that CD25 and CD26 are
expressed onCMLLSC independent of IL-3 and granulocyte colony-
stimulating factor (G-CSF) activity. In particular, no signiﬁcant
change in expression of CD25 and CD26 was found when CML
LSC were exposed to a blocking anti–G-CSF antibody, a blocking
anti–IL-3 antibody, or recombinant IL-3 (supplemental Figure 7A-D).
We also examined the effects of gliptins, imatinib, and rhCD26 on
expression of CXCR4 on CML cells. However, we were not able to
detect any change in CXCR4 expression on KU812 cells or CD341/
CD382CMLLSC after exposure to these compounds (supplemental
Figure 8). Whereas freshly isolated CB SC (CD341/CD38─) failed
to express CD26, these cells started to express low amounts of CD26
Figure 3. (Continued).
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after short-term culture (supplemental Figure 9A-B). However,
exposure of CB SC to G-CSF did not result in upregulation of CD26
(supplemental Figure 9A-B).
Successful treatment with imatinib eliminates circulating
CML LSC
Although BM and PB SC were found to express CD26 in all CML
patients at diagnosis, the expression levels and percentage of CD261
cells varied from donor to donor (Figure 1C). The percentage of
CD261 SC was found to correlate with white blood counts (Figure 4)
but did not correlate with other prognostic variables or scores (Sokal,
Hasford,EUTOS) (Figure 5).During successful therapywith imatinib,
CD261 LSC decreased substantially, and in most cases, CD261 LSC
were no longer detectable in the PB (Figure 6A-B). However, during
the initial phase of successful therapy (at month 3) residual CD261
LSC were detected and we were able to sort out these cells in one
patient. As expected, BCR/ABL1 mRNA was detectable in the re-
sidual CD261 LSC, whereas the sorted CD26─ SC did not express
BCR/ABL1 (Figure 6C). In most patients with resistant or relapsed
CML, CD261 LSCwere detectable in the PB and BM (Figure 6B,D).
We also examined the expression of CD26 on LSC in CML BP. In
most of these patients, including lymphoid BP, LSC expressed CD25,
andCD26at theprotein andmRNAlevel (supplemental Figure 10A-B).
However, in a few patients with BP, LSC did not express CD26 (sup-
plemental Figure 10A). IL-1RAP was also found to be expressed on
LSC in most BP patients (supplemental Figure 10C).
Discussion
The concept of LSC has been developed with the intention to explain
the biology and functional hierarchy of myeloid leukemias and to
develop novel curative drug therapies.6-11 CML LSC supposedly
residewithin a CD341/CD38─ fraction of the leukemic clone.7-10,25-27
However, this phenotype is shared also by normal BM SCs. We
performed gene array, PCR, and ﬂow cytometry studies to identify
novel markers of CML LSC. Of all surface antigens examined, the
surface enzyme CD26 (DPPIV) was identiﬁed as a speciﬁc, reliable,
and functionally important marker of LSC in CML. In fact, in contrast
to other antigens, only CD26 was found to be expressed invariably on
LSC in all patients but was not detectable on CD341/CD38─ SC in
normal BM samples or on LSC in other myeloid neoplasms. More-
over, in most patients with CML, CD26 was expressed only on
CD341/CD38─ LSC but not on more mature CD341/CD381
progenitors.
Several different markers are considered to be expressed more or
less speciﬁcally on LSC in CML.28-30 In the present study, we were
able to conﬁrm expression of these antigens, including Siglec-3
(CD33), Pgp1 (CD44), IL-3RA (CD123), and IL-1RAP. In par-
ticular, CD341/CD38─/CD261 LSC in CML coexpressed these
antigens in most donors. In addition, we were able to show that
CD261 CML LSC coexpress IL-2RA (CD25). Whereas CD33 and
CD123were also detectable on normal BMSC, albeit at lower levels,
CD25 and IL-1RAP were only detectable on CML LSC. However,
unlike CD26, CD25 and IL-1RAP were also found to be expressed
quite frequently on LSC in other leukemias, especially AML. With
regard to CD25, these data conﬁrm previous studies.36 As expected,
we found a good correlation between expression of CD25 and CD26
on CML LSC, but only a rough correlation between expression of
CD26 and IL-1RAP, which is best explained by the fact that in
several patients, CML LSC did not express substantial amounts of
IL-1RAP. Most cell-surface antigens detected on CML LSC were
also identiﬁed by gene array and PCR analyses in our experi-
ments, thereby conﬁrming previous studies.28,37,38 Altogether,
our data show that CD26 is a reliable and robust biomarker of
CML LSC.
To conﬁrm that CD26 is speciﬁcally expressed in CML LSC, we
puriﬁed CD261 and CD26─ SC from CP-CML samples to near
homogeneity (.98% purity) by cell sorting. As expected, only the
CD261 LSC, but not the CD26─ SC, were found to express BCR/
ABL1 byFISH and qPCR.As assessed by FISH, virtually all CD261
SC were found to be clonal cells expressing BCR/ABL1. Moreover,
only the CD261 LSC gave rise to BCR/ABL11 colonies in vitro in
Figure 4. Correlation between leukemic burden and CD261 SC in patients with
CML. (A) The comparison of the percentage of CD261 BM SC (of all CD341/CD382
cells) in patients with high white blood counts (WBC) at diagnosis (.150 G/L, n5 15, left
bar) with that in patients in whom lower WBC were measured (,150, G/L, n 5 23). (B)
The correlation between WBC and the percentage of CD261 SC in CML at diagnosis in
all patients (n5 38) are shown. (C) The comparison of the percentage of CD261SCwith
the percentage of CD261 progenitor cells (CD341/CD381) in patients with freshly
diagnosed CML are shown. As is visible, CD26 is primarily expressed in the CD341/
CD382 fraction of the leukemic clone.
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short-term and LTC-IC cultures. Finally, only the CD261 SC were
found to repopulate the NSG marrow with BCR/ABL11 cells,
whereas CD26─ SC from the same patients produced BCR/ABL1–,
nonleukemic, engraftment. These data show that CD26 is a speciﬁc
marker for CML LSC. However, we were not able to demonstrate
reproducible CML engraftment in secondary recipient mice. This
may be explained by the fact that the development of a chronic
leukemia exceeds the observation period or even the lifetime of a
mouse, which is in turn explained by the premalignant nature and
thus low proliferation rate of CML LSC.19,39 Alternatively, the
homing defect of CML LSC was responsible for the low rate and
slow time of engraftment. The possibility that only more mature
cells engrafted or even mimicked engraftment by maintenance
couldbe excluded incontrol experiments. In fact, isolatedLin1/CD34─
CML cells (SC-depleted fractions) did not produce a stable cell
population or detectable engraftment in NSGmice. Finally, our NSG
mice engrafted AML cells as full-blown leukemias in the same
NSG assay.40
In CML, the BCR/ABL1 mutation is considered an early and
decisive drivermutation that triggers various signaling pathways and
expression of diverse effector molecules in CML cells.2-4 However,
not all CML-related antigens and aberrantly expressed markers may
be triggered by BCR/ABL1.41We found that expression of CD26 on
CML LSC is not dependent solely on BCR/ABL1 activity. Notably,
BCR/ABL1 did not induce expression of CD26 in Mo7e or Ba/F3
cells, and expression of CD26 on CMLLSCwas not inhibited by the
addition of imatinib. These observations suggest that expression of
CD26 depends on other, as yet unknown, mechanisms that may be
relevant in an early phase of CML development. Alternatively, the
turnover of CD26 on the surface of CML LSC is very low, so that
inhibition of BCR/ABL1 was ineffective. We also asked whether
expression of CD26 on CML LSC is dependent on autocrine cy-
tokine stimulation. Notably, it has been described that CML LSC
produce IL-3,G-CSF, or other cytokines in an autocrine fashion.33,42-44
However, exposure to IL-3 or a neutralizing anti–IL-3R antibody did
notmodulate expression ofCD25orCD26onCMLLSC, and the same
was found with a neutralizing anti–G-CSF antibody. Therefore, the
most likely explanation is that CD26 expression is an early BCR/
ABL1-independent event in leukemogenesis that may be critical for
disease initiation and/ormanifestation. The fact that CD26 is detectable
on LSC in all patients would favor this hypothesis. Moreover, even in
primary lymphoid BP of CML (BCR/ABL11), LSC expressed CD26.
However, in one patient with BP, CD26 was no longer detectable on
LSC, and also the CML cell lines examined were found to be
CD26–. This observation suggests that in a terminal stage of di-
sease, CD26 may no longer be required to trigger the spread and
expansion of LSC.
In CML, one of the key features is the extramedullary spread of
stem and progenitor cells, resulting in overwhelming extramedullary
myelopoiesis.2,3 However, although CMLLSC are known to exhibit
a homing defect and altered response to niche-related chemokines
such as SDF-1,31-33 the exact mechanism of LSC mobilization in
CML remains unknown. In the current article, we show that CML
LSC speciﬁcally express the SDF-1–degrading surface enzyme
DPPIV (CD26). These data suggest that LSC-derived CD26 may
degrade SDF-1 and thereby blocks SDF-1–induced migration of
CML LSC. Indeed, LSC-derived CD26 was found to exhibit DPPIV
activity. In addition,wewere able to show thatCML-derivedCD26 as
well as recombinant CD26 inhibit SDF-1–induced migration of
CXCR41 leukemic cells. As expected, these effects of CD26 were
neutralized by gliptins. Together, these data show that CD26 is
a functionally active SDF-1–degrading surface enzyme expressed
Figure 5. Correlation between the numbers of
CD261 SCs and CML scores. (A-B) In 27 patients with
CML (BM samples, n 5 26; PB, n 5 1), the percentage
of CD261 SC (of all CD341/CD382 cells) and CD261
progenitor cells (of all CD341/CD381 cells) was de-
termined by flow cytometry. Percentage of CD261 SC
(left) and CD261 progenitor cells (right subpanel) in
various categories of the Sokal score (A) and Hasford
score (B). In high-risk patients, phenotypically more
mature progenitor cells tend to acquire CD26. Sokal
scoring: high (.1.2), intermediate (int) (0.8-1.2), and low
(,0.8). Hasford scoring: high (.1480), int (781-1480),
low (#780). (C) Correlations between the percentages
of CD261 SC and the 3 scoring systems. As shown, no
substantial correlation was found.
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on CML LSC. Expression of CD26 may thereby also explain the
migration and homing defect of CML LSC. This hypothesis was
further supported by the observation that CD261 LSC produced
a diffuse engraftment in the BM of NSG mice, whereas the CD26─
SC from the same patients engrafted at the endosteal region. We
also asked whether normal SC express CD26. However, although we
studied it extensively, we were unable to detect CD26 on SC obtained
from normal or reactive BM. In freshly isolated CB samples, we were
alsounable todetectCD26onCD341/CD38─SC.However, after short-
term culture, CB SC expressed low amounts of CD26. These obser-
vations suggest that under certain (in vitro) conditions, normal
(CB-derived) SC may express some CD26, which would conﬁrm
previous data.45-48 However, in contrast to a previous study,47 we
were unable to show that G-CSF promotes the expression of
CD26 on CB SC.
To validate CD26 as a new marker of CML LSC, we asked
whether CD26 expression would correlate with disease activity. To
address this question, we examined follow-up samples of our CML
patients treated with imatinib or nilotinib. At the time of complete
cytogenetic remission (CCyR) and/or MMR, CD26 was no longer
detectable on CD341/CD38─ SC in these patients, suggesting that
most CMLLSCwere suppressed, had redistributed, or were depleted
in these patients. In contrast, in patients with relapsing CML or
resistant disease, at least a subfraction of CD341/CD38─ cells co-
expressed CD26. In addition, we were able to show that the residual
CD261 SC that can be detected shortly after the start of imatinib
therapy (month 3) are BCR/ABL11 cells, whereas the CD26─ SC
isolated from the same samples are BCR/ABL1–. These data suggest
that CD26 can be used as a follow-up parameter to monitor the
presence and numbers (percentage) of CML LSC in tyrosine kinase
inhibitor–treated patients.
Finally, we addressed the question ofwhether CD26may serve as
a novel therapeutic target in CML. To test this hypothesis, we ﬁrst
incubated CML LSC with vildagliptin before injecting these cells
into NSG mice. Indeed, gliptin exposure resulted in a decreased
engraftment of CML cells. In a second step, we examined nilotinib-
treated CML patients receiving a gliptin because of uncontrolled
diabetes mellitus. We identiﬁed 2 such patients, and in both, gliptin
treatment was followed by a substantial decrease of BCR/ABL1
to undetectable or near undetectable levels. Although these data need
to be conﬁrmed in a clinical trial, they are encouraging and may
point to the important role of CD26 as an LSC target in CML.
In summary, our data show that CML LSC speciﬁcally express
CD26, and that CD26 expression is functionally important and may
disrupt SDF-1-CXCR4 interactions in the SC niche. Whether CD26
can also be used as a new SC target in CML is currently under
investigation.
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